RODI Fertility
A New Paradigm in Reproductive Immunology

RODI Fertility is transforming reproductive immunology with patented, physician-designed formulations that balance, rather than suppress, the immune system to improve implantation and early pregnancy stability. Its first-in-class NK platform and complementary hormonal and prenatal solutions give clinicians a measured, testable way to personalise care for recurrent implantation failure and miscarriage linked to alloimmune factors.

For decades, immunologic contributors to early pregnancy loss, particularly elevated natural killer (NK) cell activity and inflammatory deviation were either under-addressed or suppressed with corticosteroids or intravenous immunoglobulin (IVIG). Today, major guidelines generally advise against routine IVIG USE, except within very rare and carefully controlled studies.

RODI Fertility’s approach departs from suppression toward calibrated immunomodulation, shifting immune signalling toward tolerance during conception and the first trimester while preserving physiologic defences. The strategy is grounded in reproductive immunology’s core paradox—maternal tolerance of a semi-allogeneic embryo—and in the measurable association between NK cell absolute numbers, cytotoxicity, and implantation outcomes, which many clinicians now monitor via flow cytometry.

RODI NK Plus and RODI NK: Encoded Balance, Clinical Usability

RODI’s flagship duo, RODI NK Plus for preconception and RODI NK for the first trimester, operationalises immune equilibrium with complex lipidomics rather than single-agent omega formulations. The patented technology extracts and encapsulates a library of more than 40 rare mono and polyunsaturated fatty acids, each with defined chain lengths and saturation profiles, and combines them with vitamin D3, which enhances the immunomodulatory effects of the fatty acids. This influences antigen presentation, T-cell deviation, and NK dynamics in a reproducible way.

Patients take RODI NK Plus once daily for 40 consecutive days before trying to conceive. During pregnancy, RODI NK provides a continuation protocol calibrated for the first three months. This oral, non-invasive, GMP-standard program is designed by physicians, supported by published, award-winning clinical studies, and aligned with European and international quality frameworks.

“RODI NK Plus prepares your immune system before conception, while RODI NK supports the first trimester of pregnancy. They balance rather than suppress immune activity. Together, they help normalize NK cell levels prior to conception and promote healthy immune tolerance to the fetus early in pregnancy,” states Dr. Barbara Geladakis, MD, founder and CEO.

How the Fatty-Acid Matrix Stands Out

Fatty acids are structural and signalling mediators that can up- or down-shift discrete immune responses depending on dose, ratios and metabolic context. RODI Fertility’s R&D team iterated for seven years to map those contextual inflexions into a stable, patient-ready blend. By precisely controlling composition and bioavailability, the formulations aim to reduce excessive NK cytotoxicity and restore Th1/ Th2 balance without inducing broad immunosuppression. Minor deviations in ratios can invert immunologic effects. The patented process protects that calibration across manufacturing lots, which is essential for clinical reproducibility in IVF protocols and timed natural cycles.

Clinicians can integrate the products into care pathways anchored by lab endpoints: many IVF teams already trend NK percentage/cytotoxicity pre and post-RODI NK Plus to confirm movement toward reference ranges before embryo transfer. In Greece—RODI’s first launch market—the products earned sustained physician endorsement and repeated sell-outs. Clinics reported improved implantation in patients with recurrent losses or failed transfers, aided by the ability to show before-and-after immune shifts on standard assays. The oral monodose format, favourable sensory profile, and absence of reported contraindications, aside from caution regarding soybean allergy, support adherence during the critical preconception window.

Portfolio Logic Across the Journey

RODI Fertility’s portfolio is grouped into immune equilibrium, oocyte quality/hormonal regulation, and foundational micronutrition. The immune pillar comprises RODI NK Plus (preconception) and RODI NK (first trimester), along with Vitamin D-fortified supplements to support normal immune function during their respective time frames.

The oocyte/hormonal pillar centres on RODI OVA, a day-and-night sachet system containing myo-inositol, B vitamins, folate, selenium, melatonin and related cofactors. It helps normalise FSH/LH balance and support egg quality over at least three months, including in later reproductiveage cohorts. The foundation pillar is RODI Vita, a once-daily prenatal multivitamin engineered with slow-release delivery to stabilise serum nutrient levels and improve GI tolerability.

The production is helmed in Italy under GMP, with European-sourced ingredients underpinning quality. The formulations are structured to comply with EU, FDA, and Middle Eastern frameworks for food supplements with defined health claims. RODI’s methods and products are protected by patents in major global markets and have expanded from Greece to other countries, with preparations underway for broader distribution at leading pharmaceutical exhibitions. Positioning NK Plus and NK as first-in-class and first-to-market in immune-modulating fertility nutrition differentiates them from commodity omega oils and over-the-counter periconceptionals.

Leadership Philosophy and Clinical Adoption

The leadership’s motto—conceive your dream—pairs scientific rigour with patient-centred empathy, emphasising that breakthroughs must translate into fewer failed cycles and an increase in healthier first trimesters. Clinics increasingly embed RODI NK Plus as a pre-transfer standard in immunology-positive cases and continue with RODI NK into the first trimester.

At the same time, OVA and Vita address endocrine resilience and micronutrient continuity for broader fertility cohorts. This end-to-end framework resonates with IVF centres specialising in immunologic and unexplained infertility, where modular, evidence-informed adjuncts can move marginal cycles into viable pregnancies.

Across thousands of uses since launch, practitioners highlight three adoption drivers: measurable immune normalisation on flow cytometry before embryo transfer, improved implantation rates among patients with repeated implantation failure, and an accessible, at-home regimen that avoids hospital infusions and fits within standard IVF timelines and normal conception as well. The formulations use natural ingredients, are vegetarian and include a soybean allergy caution on the pack. Otherwise, no contraindications have been reported in the market, and the taste and dosage design have been optimised for daily adherence.

“We believe that rigorous research leads to scientific breakthroughs, and by using innovative, intelligent solutions, we aspire to assist women in conceiving their dreams,” says Dr. Geladakis.

Standardising Immunologic Personalisation

As reproductive medicine advances, immunologic personalisation will likely become a standard axis alongside genetics and embryology, with validated adjunct therapies that tune tolerance rather than silence immunity. RODI Fertility’s patented NK platform and clinician-authored protocols are well-positioned to anchor that shift. It is simple to deploy, measurable in routine labs and manufactured to pharmaceutical standards as food supplements with defined health claims.

For those whose loss has been deemed “unexplained” one too many, transforming immune noise into a readable, actionable signal may be the edge that turns possibility into pregnancy.